Cross-Border Impact Ventures

OxCan is a startup focused on early lung cancer detection using machine learning and liquid biopsy techniques. The company has developed an artificial intelligence-based healthcare platform that identifies cancer through targeted blood testing. This platform effectively detects cancer-related materials released into the bloodstream, allowing for cost-effective and routine analysis. It evaluates multidimensional liquid biopsy results, including DNA, proteins, epigenetic factors, as well as incorporating epidemiological data and patient medical histories. By providing healthcare providers with the tools for early cancer detection, OxCan aims to facilitate timely and potentially curative treatment options.

OncoLens is a technology company that focuses on enhancing cancer treatment planning and management through a HIPAA-compliant mobile and web-based platform. Its innovative solution consolidates various data sets, oncology care teams, and stakeholders into a single platform, facilitating multi-disciplinary treatment planning and improving clinical decision-making. By automating tumor board management and survivorship care planning, OncoLens streamlines business processes and enhances accreditation and quality reporting. The platform's AI-driven clinical decision support capabilities empower physicians to collaboratively create and discuss individualized treatment plans for cancer patients, ultimately aiming to improve patient outcomes and streamline oncology workflows.

Raydiant Oximetry, Inc. is a medical device company founded in 2015 and headquartered in Mountain View, California. The company focuses on improving childbirth outcomes for mothers and infants by developing a low-cost, non-invasive device that monitors fetal oxygen levels during labor. This innovative technology aims to provide real-time insights into fetal oxygenation, which can help clinicians make informed decisions and reduce the risks associated with childbirth, such as birth injuries and unnecessary cesarean sections. By enhancing patient care and potentially lowering healthcare costs, Raydiant Oximetry's device addresses critical needs in maternal and fetal health.

Axena Health is a women-led company focused on enhancing the lives of women suffering from pelvic floor disorders through innovative digital technology. The company specializes in developing solutions for urinary incontinence and chronic fecal incontinence, conditions that are often underreported. Its flagship product, the Leva Pelvic Health System, is a prescription digital therapeutic that provides at-home treatment options. Utilizing patented technology, the system offers non-invasive and drug-free solutions by providing real-time visualization of pelvic floor movements while monitoring progress and usage. This approach enables women to effectively strengthen their pelvic floor muscles and alleviate symptoms associated with various types of incontinence, including stress, mixed, and urgency incontinence.

OncoLens is a technology company that focuses on enhancing cancer treatment planning and management through a HIPAA-compliant mobile and web-based platform. Its innovative solution consolidates various data sets, oncology care teams, and stakeholders into a single platform, facilitating multi-disciplinary treatment planning and improving clinical decision-making. By automating tumor board management and survivorship care planning, OncoLens streamlines business processes and enhances accreditation and quality reporting. The platform's AI-driven clinical decision support capabilities empower physicians to collaboratively create and discuss individualized treatment plans for cancer patients, ultimately aiming to improve patient outcomes and streamline oncology workflows.

Sonio is an AI-based support platform for fetal ultrasound, helping practitioners analyze and diagnose congenital malformations. Sonio combines the patient’s medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis. It assists sonographers during prenatal screening scans, helping them ensure that they have not forgotten anything, take risk factors into account, and facilitate the sharing of images with patients and other health professionals.

Daye Ltd is a gynecological health company based in London, United Kingdom, founded in 2018. The company develops, manufactures, and markets female hygiene products under the Your Daye brand, specializing in innovative tampons designed to address period-related issues. Notably, Daye offers CBD-infused tampons that provide a natural alternative to traditional painkillers for managing menstrual cramps. In addition to its tampons, Daye is creating an at-home vaginal microbiome screening kit that allows women to test for infections and microbiome disruptions conveniently. This kit aims to empower women in monitoring their gynecological health, potentially reducing the risk of sexually transmitted infections, gynecological cancers, and complications related to fertility and IVF. Furthermore, Daye plans to launch a comprehensive digital platform focused on gynecological health, aiming to alleviate the challenges women face throughout their health journeys from menstruation to menopause.

Macro-Eyes, Inc. is a machine learning company focused on enhancing access to healthcare through its innovative solutions. Its primary product, Sibyl, employs artificial intelligence for intelligent patient scheduling, which has shown a capability to improve patient utilization by 15%, enabling healthcare providers to see more patients without extending clinical hours. This technology is built on extensive research and deployment of AI for clinical decision support at prominent institutions, including Stanford University and major health systems in the United States. The company has garnered support from the Bill & Melinda Gates Foundation to develop a predictive supply chain for health, aimed at optimizing resource allocation at individual health facilities and pharmacies to prevent stock-outs and reduce waste. Additionally, Macro-Eyes is collaborating with the California Primary Care Association to implement Sibyl across 1,800 health facilities, thereby furthering its mission to increase access to life-saving care.